Genmab (GMAB) has released an update.
Genmab A/S, the Copenhagen-based biotechnology firm, has been actively executing its share buy-back program, repurchasing shares as part of a DKK 3.5 billion initiative that is slated for completion by December 16, 2024. From June 3 to June 7, 2024, the company bought back a total of 18,225 shares, adding up to a significant investment of DKK 35,172,035.85. This strategic move underlines Genmab’s commitment to its shareholders and is conducted in compliance with EU regulations.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.